罗米地辛联合来那度胺治疗初治外周T细胞淋巴瘤的多中心2期研究
这项多中心2期研究评估了罗米地辛联合来那度胺作为年龄>60岁或不适合化疗的初治外周T细胞淋巴瘤患者的无化疗初始治疗方案。29例患者中位年龄75岁,总缓解率65.2%,完全缓解率26.1%,中位缓解持续时间10.7个月,2年无进展生存率31.5%,2年总生存率49.5%。
要点
- 罗米地辛联合来那度胺在初治PTCL中总缓解率65.2%,完全缓解率26.1%
- 血管免疫母细胞性T细胞淋巴瘤亚组总缓解率78.6%,完全缓解率35.7%
- 3-4级血液学毒性包括中性粒细胞减少45%、血小板减少34%、贫血28%
核心结论
- 该研究首次证明罗米地辛与来那度胺的生物学联合方案作为PTCL初始治疗可行且有效,值得进一步评估。
研究设计与样本
- 多中心2期研究,纳入29例年龄>60岁或不适合化疗的初治PTCL患者,中位年龄75岁。
- 治疗方案为罗米地辛10 mg/m2静脉注射第1、8、15天,来那度胺25 mg口服第1至21天,28天为一周期,最长治疗1年。
- 主要终点为总缓解率,次要终点包括安全性和生存。
主要发现
- 29例患者中16例(55%)为血管免疫母细胞性T细胞淋巴瘤,10例(34%)为PTCL-非特指型,2例为ATLL,1例为EATL。
- 中位随访15.7个月时,23例可评估患者接受中位6个周期治疗,总缓解率65.2%,完全缓解率26.1%。
- 血管免疫母细胞性T细胞淋巴瘤亚组总缓解率78.6%,完全缓解率35.7%。
- 中位缓解持续时间10.7个月,达到完全缓解的患者中位缓解持续时间27.1个月。
- 估计2年无进展生存率31.5%,2年总生存率49.5%。
关键数值与推荐
- 3-4级血液学毒性:中性粒细胞减少45%,血小板减少34%,贫血28%。
- 3-4级非血液学毒性:低钠血症45%,高血压38%,低白蛋白血症24%,乏力17%,高血糖14%,低钾血症14%,脱水10%,感染10%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出该方案值得进一步评估,表明需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphomas (PTCLs) are associated with poor prognosis when treated with cytotoxic chemotherapy. We report the findings of a phase 2 study evaluating a chemotherapy-free combination of romidepsin plus lenalidomide as initial treatment for patients with PTCL who were aged >60 years or noncandidates for chemotherapy. Treatment was initiated with romidepsin 10 mg/m2 IV on days 1, 8, and 15 and lenalidomide 25 mg taken orally from days 1 to 21 of 28-day cycle for up to 1 year. The primary objective was overall response rate (ORR). Secondary objectives included safety and survival. The study enrolled 29 patients with a median age of 75 years, including 16 (55%) angioimmunoblastic T-cell lymphoma (AITL), 10 (34%) PTCL- not otherwise specified, 2 ATLL, and 1 EATL. Grade 3 to 4 hematologic toxicities included neutropenia (45%), thrombocytopenia (34%), and anemia (28%). Grade 3 to 4 nonhematologic toxicities included hyponatremia (45%), hypertension (38%), hypoalbuminemia (24%), fatigue (17%), hyperglycemia (14%), hypokalemia (14%), dehydration (10%), and infection (10%). At median follow-up of 15.7 months, 23 patients were evaluable and received a median treatment of 6 cycles. The ORR was 65.2% with complete response (CR) at 26.1%, including 78.6% ORR and 35.7% CR for AITL. Median duration of response was 10.7 months, with 27.1 months for patients achieving CR. The estimated 2-year progression-free survival was 31.5%, and 2-year overall survival was 49.5%. This study provides the first demonstration that the biologic combination of romidepsin and lenalidomide is feasible and effective as initial therapy for PTCL and warrants further evaluation. This trial was registered at www.clinicaltrials.gov as #NCT02232516.
引用
- Ruan J, Zain J, Palmer B, et al. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Adv. 2023. PMID: 37327113. doi:10.1182/bloodadvances.2023009767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。